Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Follicular 2Lymphoma 2Weight Loss 1Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Splenomegaly 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphocytosis 1Lymphadenopathy 1Lung Neoplasms 1Kidney Neoplasms 1Insulin Resistance 1Immunoblastic Lymphadenopathy 1Hyperglycemia 1Hodgkin Disease 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32Etoposide 31venetoclax 30Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Metformin × Lymphoid × Clear all
NCT01324180 2017-08-07

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
14 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡